a regenerative medicine company seeking to address a shortage of organs for transplantation.

Summary

Videregen is a regenerative medicine company seeking to address a shortage of organs for transplantation. The company’s focus is on the treatment of bronchopleural fistula (BPF) – a medical complication where an abnormal passageway forms in the lungs following lung surgery, chemotherapy, or an infection.

Using stem-cell based technology, the company is developing biological ‘scaffolds’ from the donated organ/tissue to which it then adds the patient’s own stem cells, in turn creating a bespoke organ replacement. The use of the patient’s own cells (taken from their bone marrow) aims to reduce the likelihood that the patient’s body may reject the implant.

Product

Life Sciences EIS

Sector

Regenerative medicine

Status

Open

HMRC

Advanced Assurance